Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Cheap Narrow Moat ASX share continues to face negative sentiment
Earnings growth fails to excite investors worried about AI disruption.
stocks
ASX energy giant remains cheap following record production
Impressive cost control and record production leads to higher dividend.
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.10 | 12.80 | 0.14% |
| CAC 40 | 8,519.21 | 22.04 | 0.26% |
| DAX 40 | 24,986.25 | 5.72 | -0.02% |
| Dow JONES (US) | 49,174.50 | 370.44 | 0.76% |
| FTSE 100 | 10,680.59 | 4.15 | -0.04% |
| HKSE | 26,590.32 | 491.59 | -1.82% |
| NASDAQ | 22,863.68 | 236.41 | 1.04% |
| Nikkei 225 | 57,906.95 | 585.86 | 1.02% |
| NZX 50 Index | 13,523.27 | 9.04 | -0.07% |
| S&P 500 | 6,890.07 | 52.32 | 0.77% |
| S&P/ASX 200 | 9,094.10 | 10.00 | 0.11% |
| SSE Composite Index | 4,117.41 | 35.34 | 0.87% |